T-Cell Receptor Single-Chain Antibody IgG1-Fc Fusion Proteins as Bispecific Engagers for Natural Killer and T Cells
Cells · 2026
DOI: 10.3390/cells15171545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Annkathrin C Teschner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Killer Cells, Natural, Immunoglobulin G, Recombinant Fusion Proteins, T-Lymphocytes. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Center for Tumor Diseases (NCT Heidelberg, Germany) 3.0 Immunotherapy Program "Preclinical Development of Tumor-Reactive Bispecific Antibodies, National Center for Tumor Diseases.
Abstract (Originalsprache)
Soluble variants of recombinant T cell receptors (TCRs) have become attractive tools for the retargeting of cytotoxic T cells toward intracellular tumor or viral antigens by combining them with CD3-binding antibodies in bispecific T cell engagers; however, TCR-based NK cell engagers have not been studied so far. Here, we developed TCR-based bispecific agents for the redirection of NK cells utilizing a bivalent IgG1-like format. Trifunctional NK engagers included an Fc part with enhanced binding to FcγRIII/CD16A and single-chain (scFv) antibodies recognizing either NKp46 or CD16A, activating NK cell receptors. HCMV pp65/HLA-A2 reactive TCR-scFv-Fc fusion proteins incorporating an affinity-matured TCR and anti-NKp46 scFv activated peripheral blood NK cells and induced cytotoxicity in an antigen-specific manner. For T cell redirection, TCR-scFv-Fc fusion proteins included an scFv antibody recognizing CD3ε. Compared with NK cell engagers, T cell engagers showed similar sensitivity but lower peptide selectivity. For two TCRs recognizing melanoma-associated peptides, affinity-matured TCR-scFv-Fc fusion proteins enabled NK and T cell redirection and activation, and killing of tumor target cells loaded with exogenous peptides. Our results expand the versatility of the soluble TCR technology to NK cell engagers; however, they still require improvement in sensitivity to target tumor cells with low peptide/MHC-I complex densities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
- Department of Medical Oncology, Heidelberg University Hospital, Heidelberg University, 69120 Heidelberg, Germany.
ORCID-Profile: Annkathrin C Teschner, Márcia Gonçalves, Marten Meyer, Frank Momburg
Förderung
- the National Center for Tumor Diseases (NCT Heidelberg, Germany) 3.0 Immunotherapy Program "Preclinical Development of Tumor-Reactive Bispecific Antibodies
- National Center for Tumor Diseases
Zitieren
APA
Teschner, A. C., Gonçalves, M., Meyer, M., Zörnig, I., Jäger, D., & Momburg, F. (2026). T-Cell Receptor Single-Chain Antibody IgG1-Fc Fusion Proteins as Bispecific Engagers for Natural Killer and T Cells. Cells. https://doi.org/10.3390/cells15171545
Vancouver
Teschner AC, Gonçalves M, Meyer M, Zörnig I, Jäger D, Momburg F. T-Cell Receptor Single-Chain Antibody IgG1-Fc Fusion Proteins as Bispecific Engagers for Natural Killer and T Cells. Cells. 2026. doi:10.3390/cells15171545
BibTeX
@article{Teschner2026,
author = {Teschner, Annkathrin C and Gonçalves, Márcia and Meyer, Marten and Zörnig, Inka and Jäger, Dirk and Momburg, Frank},
title = {T-Cell Receptor Single-Chain Antibody IgG1-Fc Fusion Proteins as Bispecific Engagers for Natural Killer and T Cells},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15171545}
}
EUVIMED